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Introduction
Drug resistance causes immense human suffering globally
and is one of the best documented examples of evolution
in real time. No self-respecting introductory evolution
text fails to mention this, and several professional evolu-
tion societies give this as a major practical argument for
the teaching of evolution and continued investment in
evolutionary science (Meagher and Futuyma 2001). Yet
the drug resistance ﬁeld is – with a few outstanding
exceptions – dominated by people with no training in
evolutionary biology. Indeed, the microbiologists, clini-
cians and public health practitioners who publish on drug
resistance do not even much use the word ‘evolve’– they
more naturally use ‘emerge’, ‘spread’ or ‘arise’ (Antonovics
et al. 2007). The vast majority of publications on the
evolution of antibiotic resistance are in the medical ﬁeld
and not in academic evolutionary biology or genetics
journals (Antonovics et al. 2007).
Why do so few professional evolutionary biologists
work on drug resistance evolution, particularly given the
commercial and grant money involved? This is certainly a
speciﬁc instance of the remarkable antipathy of most
evolutionary biologists to utilitarian science (the journal
Evolutionary Applications appeared 17 years after the ﬁrst
issue of Ecological Applications), an antipathy historians of
science have yet to explain. But in the case of drug
resistance, the overwhelming volume of data does make
assimilating the relevant natural history a challenge,
especially as the data are elucidated by physicians, veteri-
narians, microbiologists and public health specialists, so
that a foreign, often pathogen-speciﬁc jargon and intellec-
tual culture dominates. Moreover, drug resistance, like
many biomedical problems, is perhaps not so interesting
to those attracted to evolutionary biology by a passion for
‘natural’ natural history.
But we think it goes deeper than this. Based on an
entirely ad hoc, nonrandom sample of our colleagues (lar-
gely the evolutionary biologists we meet at conferences),
we believe the main reason evolutionary biologists avoid
drug resistance is that evolutionary biologists consider
drug resistance to be conceptually uninteresting. And at
one level it is. As Antonovics et al. (2007) point out, ‘the
evolution of antibiotic resistance, while critically impor-
tant from a medical view point, is no longer in and of
itself a novel ﬁnding in evolutionary biology’. This is true
of course, but the evolutionary processes which determine
patterns of drug resistance are a different issue. Our straw
Keywords
antibiotic resistance, drug resistance, malaria,
Plasmodium.
Correspondence
Andrew F. Read, Center for Infectious
Disease Dynamics, Departments of Biology
and Entomology, Pennsylvania State
University, University Park, PA 16827, USA.
Tel.: +1 814 867 2396; fax: +1 814 865
9131; e-mail: a.read@psu.edu
Received: 5 December 2008
Accepted: 11 December 2008
doi:10.1111/j.1752-4571.2008.00066.x
Abstract
Evolutionary biologists have largely left the search for solutions to the drug
resistance crisis to biomedical scientists, physicians, veterinarians and public
health specialists. We believe this is because the vast majority of professional
evolutionary biologists consider the evolutionary science of drug resistance to
be conceptually uninteresting. Using malaria as case study, we argue that it is
not. We review examples of evolutionary thinking that challenge various falla-
cies dominating antimalarial therapy, and discuss open problems that need
evolutionary insight. These problems are unlikely to be resolved by biomedical
scientists ungrounded in evolutionary biology. Involvement by evolutionary
biologists in the science of drug resistance requires no intellectual compro-
mises: the problems are as conceptually challenging as they are important.
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consider these processes conceptually simple (mutation,
selection, ﬁxation), and any solutions largely obvious
(combination therapy, reduced drug use). The general
feeling seems to be that drug resistance provides excellent
examples with which to begin evolution classes and intro-
ductory textbooks, and an excellent vehicle to get across
basic population genetics. But it is not believed to be an
intellectually challenging pursuit around which to struc-
ture an interesting evolutionary research program.
Here we attempt to counter this view. We believe there
is a strong case for advanced classes in drug resistance
evolution, and also that there are numerous conceptually
challenging problems in drug resistance evolution to
which evolutionary biologists can make unique contribu-
tions. The solution of these problems would both be
intellectually rewarding and could reduce human suffer-
ing. We make this case using malaria, with which we are
most familiar, but we believe similar arguments can be
made for almost any infectious disease.
We illustrate our case by reviewing a series of fallacies
which were, or still are, held by the malaria community
(albeit here translated into evolutionary language), and
we ﬁnish with a number of very open evolutionary
research questions. Throughout, we have picked examples
which we think are both interesting and challenging, and
which demonstrate the practical contribution evolutionary
biology is making, or could make, to help alleviate the
medical problems caused by drug resistance. By way of an
aside, we emphasize that none of this is intended as an
argument against fundamental evolutionary research
(clearly everything we discuss here builds on that founda-
tion), or a critique of those biologists – evolutionary or
otherwise – currently engaging with drug resistance. Our
point is that the proportion of evolutionary biologists
working on drug resistance is tiny compared with the
importance and size of the problem – and the conceptual
interest of the issues involved.
The malaria drug resistance problem
Malaria parasites have evolved resistance to all classes of
antimalarials that have gone into widespread use, except
for the recently deployed artemisinin derivatives (Roll
Back Malaria 2008). Resistance was ﬁrst reported from
the ﬁeld between 1 and 15 years after introduction,
depending on the drug (Fig. 1; Peters 1987, Hyde 2005)
with drugs failing (i.e. being withdrawn from use by
national authorities) years or even decades after that. For
instance, chloroquine was widely deployed after the Sec-
ond World War, with resistance ﬁrst seen in the ﬁeld in
1957 in Thailand (Talisuna et al. 2004). Molecular evolu-
tion studies show that chloroquine resistance arose only a
handful of times, from which it spread world wide
(Fig. 2A). It never arose in Africa. Chloroquine was ﬁrst
withdrawn as a ﬁrst line drug from Thailand in 1973
(Talisuna et al. 2004) and is now recommended only for
central America, where parasites are still susceptible
(WHO 2008). High level sulphadoxine–pyrimethamine
(SP) resistance was observed within the same year as it
was introduced in Thailand in 1967 (Talisuna et al.
2004), but replaced chloroquine as ﬁrst line treatment in
most African countries in the early 1990s. Resistance
against SP is now widespread. Similar to chloroquine
resistance, the major cause of SP resistance in Africa is
thought to be a consequence of a selective sweep from a
single introduction from southeast Asia (Fig. 2B) (Roper
et al. 2004). There may also have been an African origin
Figure 1 History of the introduction of antimalarial drugs and the ﬁrst detection of resistance in the ﬁeld. The following abbreviations are used:
CQ, chloroquine; PG, proguanil; Pyr, pyrimethamine; SP, sulphadoxine–pyrimethamine; Mef, meﬂoquine; Hal, halofantrine; ACTs, artemisinin com-
bination therapies; Ato, atovaquone; Ato-PG, atovaquone–proguanil combination (malarone); LD, LapDap (chlorproguanil–dapsone). R as sufﬁx
denotes resistance. Figure redrawn from Hyde (2005).
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have spread far. Current hopes rest on artemisinin and its
derivatives, which have become the key element in cur-
rent malaria control plans (Roll Back Malaria 2008). Ar-
temisinins are used in co-formulations with other
antimalarial agents (artemisinin combination therapy,
ACT) in an attempt to minimize the chances of resistance
arising. So far this seems to be working, although there
are recent reports of parasites with reduced sensitivity to
some ACTs (White 2008) and artemisinin resistance can
be readily generated in the laboratory (Afonso et al. 2006;
Puri and Chandra 2006).
The evolution of drug resistance by malaria parasites is
now accepted as inevitable by the World Health Organi-
zation (WHO 2006), and a key component of the recently
released global malaria action plan (GMAP) is an explicit
plan for a drug delivery pipeline – intended as open-
ended so long as malaria parasites still exist (Roll Back
Malaria 2008). This is the so called ‘drug treadmill’, the
rolling-out of new drugs which will inevitably fail in the
face of parasite evolution. The GMAP estimates of the
cost of this pipeline are as follows. The basic research
budget is estimated as $US34 million per year, and the
development cost of bringing a new compound to market
at $US250 million over 10 years. The budget for reformu-
lation of compounds already in use (new combinations
for instance) is put at $US25 million over 2–6 years.
Given the rate at which existing drugs are rendered use-
less by evolution (in many cases, faster than the speed
with which new compounds can go through regulatory
processes), and the few useful compounds currently avail-
able, GMAP estimates that two new active ingredients for
(A)
(B)
Figure 2 The history of chloroquine and high level pyrimethamine–sulphadoxine (SP) resistance inferred from molecular evolution studies.
Chloroquine resistance has spread globally from selective sweeps from ﬁve independent origins, none of them in Africa where the health burden
of drug resistance is greatest. Resistance to SP is tracked by analyses of the dhfr gene which primarily confers resistance to the pyrimethamine
component. The timing of two of the independent origins is unclear. SP resistance may have several local origins in Kenya (denoted by ‘????’),
but the majority of SP-resistant infections are a consequence of a selective sweep from a single origin in South East Asia. Figure 2A is redrawn
from Wellems (2004), Fig. 2B is a summary of data from Cortese et al. (2002), Nair et al. (2003), Roper et al. (2003, 2004), McCollum et al.
(2006, 2007, 2008), Maiga et al. (2007), Mita et al. (2007), Hayton and Su (2008), Saito-Nakano et al. (2008).
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use will need to be discovered and brought to market in
the coming decade. Over the same period, 14 reformula-
tions of existing and new compounds will need to be
developed. Thus, the costs of the pipeline for R&D alone
(i.e. excluding the production and deployment costs) will
be in excess of $US2.5 billion for the coming decade to
get things up to speed. Once the currently inadequate
drug arsenal is rebuilt, $US1.5 billion will be required
every decade that follows. These are incredible amounts
of money for a disease affecting some of the poorest peo-
ple on the planet.
The challenge for evolutionary biologists is to devise
ways to slow the drug treadmill. This includes the demo-
lition of any evolutionarily-naı ¨ve medical orthodoxies
which drive the treadmill faster. The speed of the tread-
mill is set primarily by the rate at which mutations con-
ferring resistance escape the clutches of stochastic loss
and establish in a population, and then the rate at which
they subsequently spread. The WHO considers a drug
ineffective once 10% of the parasites in a population have
become resistant (WHO 2006, p. 15). Reviews of malaria
drug resistance from a population genetics perspective are
provided by Hastings and D’Alessandro (2000), Hastings
(2001), Koella and Antia (2003), Barnes and White
(2005) and Mackinnon (2005), and from the more domi-
nant drug discovery, biochemistry or pharmacokinetic
perspective by Hastings et al. (2002), White (2004), Hyde
(2005), Barnes et al. (2008), Hayton and Su (2008) and
Stepniewska and White (2008). The current WHO guide-
lines for drug use at national and individual patient levels
are published by the WHO (2006).
Fallacy 1: Drugs active against transmission stages
slow the spread of resistance
It is apparently conventional wisdom among malariolo-
gists that the spread of resistance can be slowed by drugs
which target the parasite stages responsible for infecting
mosquitoes (sexual stages called gametocytes). For
instance Mendez et al. (2002, p. 237) state that ‘Antima-
larial drugs and drug combinations designed to eliminate
both asexual and sexual parasites may deserve priority
[…] because they will reduce the spread of drug resis-
tance in its earliest stages’. Similarly, the WHO (2006, p.
141) says that ‘Reducing transmission is fundamental to
the curtailment of drug resistance’, and Barnes and White
(2005, p. 230) state that ‘...reducing the carriage of
gametocytes […] is necessary to limit the transmission of
malaria parasites and the spread of antimalarial resis-
tance’. The intuition behind this orthodoxy is that attack-
ing transmission stages reduces the chances of
transmitting a resistant mutant.
But as Hastings (2006a) has pointed out, this argument
makes little evolutionary sense. It is true that gametocyto-
cidal drugs will reduce transmission, but they will do so
most strongly for sensitive parasites. The relative ﬁtness
of resistant and sensitive strains determines the rate of
spread of resistance, and this will be increased by drugs
targeting transmission stages. Imagine an individual
infected with susceptible parasites and a few resistant
mutants. If drug treatment kills all susceptible gameto-
cytes, only the few resistant gametocytes will remain.
Now imagine treatment with a drug which kills only the
replicative (asexual) stages. Susceptible gametocytes
remain viable in the blood for weeks, and so will
co-occur with the resistant gametocytes. The relative
ﬁtness of the resistant mutants is lower in the second
scenario compared to the ﬁrst one. All else being equal,
gametocytocidal drugs will enhance the rate at which
resistant parasites rise in frequency in a population.
This can turn into a signiﬁcant effect because small rel-
ative ﬁtness differences compound through time. Using a
population genetics model, Hastings (2006a) has shown
that where drug use is common in a population, the
enhanced ﬁtness advantage conferred by gametocytocidal
drugs on resistant strains can reduce the useful therapeu-
tic lifespan of a drug by about a year (15%) compared to
nongametocytocidal therapy. There may still be sound
reasons for using drugs which target transmission stages
(e.g. reductions in infectiousness, reducing case incidence,
or an incidental side-effect of high lethality against blood
stages), but resistance management is not one of them.
Indeed, these other reasons need to be weighed against
the enhanced resistance evolution that such drugs will
prompt.
Fallacy 2: Drugs with long half lives are
preferable
Drugs that are slowly eliminated from the body after
treatment have several clinical advantages. Clearly, they
provide longer term protection against re-infection. For
SP, this can be up to 2 months, which in a high transmis-
sion region can help prevent novel infections interfering
with recovery or generating new symptoms. Slowly elimi-
nated drugs also require fewer administrations to achieve
clearance, reducing problems of patient compliance.
However, as Watkins and Mosobo (1993) pointed out,
drugs with long clearance times also impose stronger
selection for drug resistance. This is because, for similar
treatment rates, parasites are substantially more likely to
encounter drugs with long half lives. If a course of artesu-
nate persists for 5 days, the drug pressure exerted by SP
is 10 times greater (Hastings et al. 2002). Drug half life is
typically left out of models of drug resistance, yet it may
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lifespan of a drug (Hastings et al. 2002). From the resis-
tance management perspective, drugs which are rapidly
eliminated from the body are preferable.
An important corollary of this argument is that half
lives of drugs used for combination therapy should be
similar (Hastings et al. 2002; Hastings and Watkins
2006). The more dissimilar the elimination rates, the
greater the chances that resistance to one of the compo-
nent compounds can become established in a population,
thus effectively reducing combination therapy to mono-
therapy. To achieve clearance with artemisinins alone
takes a 7-day treatment regime. Because adherence to a 7-
day course is typically poor, the current WHO policy is
to combine it with a slowly eliminated antimalarial drug
(WHO 2006; White 2008). Recent reports of the failure
of these combinations seem to be due to the failure
of the partner compound (e.g. Wongsrichanalai and
Meshnick 2008). This is likely to continue whenever the
partner is a slowly cleared compound. If so, rapid reform-
ulation of ACTs is going to be an open-ended necessity,
or there will need to be an abandonment of the aim of
complete clearance following ACT.
Fallacy 3: De novo resistance mutations are the
main enemy
Current malaria treatment guidelines for uncomplicated
malaria are radical parasitologic cure (WHO 2006). This
is achieved by the administration of sufﬁciently high
and repetitive drug dosages to ensure a kill of every par-
asite in an infection, and recommended patient treat-
ment regimes are explicitly designed to do this. A major
motivator behind this is that ‘[r]esistance can be pre-
vented, or its onset slowed considerably, by […] ensur-
ing very high cure rates through full adherence to
correct dose regimens’ (WHO 2006, p. 12). The under-
lying reasoning is that complete parasitologic cure (i)
reduces parasite biomass and thus the chances of resis-
tance mutations occurring (e.g. White 2004; WHO 2006,
p. 165), and (ii) minimizes the number of parasites
exposed to sub-curative drug dosages which favor ‘toler-
ant’ parasites (e.g. Hastings and Watkins 2006). Tolerant
parasites are mutants which are not fully resistant but
are able to survive subcurative doses and so are a muta-
tional step towards full resistance (Hastings and Watkins
2006).
However, there are very few data demonstrating that
resistance arising de novo within a patient is a clinically
relevant source of drug failure in malaria patients. Indeed,
as we summarized above, the evolutionary history of
resistance to two of the major antimalarials, chloroquine
and SP, argues that it is effectively zero. Resistance to
both drugs arose just a handful of times and spread
worldwide (Fig. 2). Indeed, chloroquine resistance seems
never to have arisen de novo in Africa: it was imported
from Asia. So far as is known, every patient in Africa with
chloroquine-resistant parasites got them from other peo-
ple, never from mutational processes within their own
infections. Most high-level SP resistance in Africa was
similarly due to a single selective sweep of resistance
introduced from SE Asia (Fig. 2).
Given this, the widespread conventional wisdom that
patients should take a full course of chloroquine to slow
resistance evolution makes little sense. Indeed, chloro-
quine resistance clearly failed to arise in Africa despite
widespread underdosing as a consequence of the eco-
nomically driven noncompliance and low quality drugs
(Djimde et al. 1998; Goodman et al. 2007; Bate et al.
2008). Moreover, the recommended patient treatment
regimes of overwhelming drug treatment, way beyond
what is needed on clinical grounds, imposes the strongest
possible selection in favor of resistance, possibly for little
clinical gain. Indeed, there is an inconsistency at the heart
of the current WHO (2006) guidelines. Correctly, there
is a strong argument for reducing unnecessary use of
antimalarials at a population level, so as to minimize
selection for resistance. In contrast, the recommendation
at the single patient level is overwhelming drug use even
when there is no clinical need. This maximizes selection
for resistance.
De novo resistance may not be irrelevant for all anti-
malarials, and where single point mutations confer high
level resistance as, for example against atovaquone
(White 2004), de novo mutations may be a serious issue
clinically. But for at least high level chloroquine and SP
resistance, for which there is the best data on the evolu-
tionary history, resistance arose so rarely that the de novo
origin of resistance can be ignored as a clinical concern.
The explanation for the rare origins is almost certainly
because complete resistance with high viability involves
multiple mutations (Hastings and Watkins 2006), and so
requires a highly unlikely series of mutational events to
occur simultaneously. Current combination therapy rec-
ommendations are – rightly – designed to make artemisi-
nin resistance similarly unlikely (WHO 2006). When
resistance against artemisinins does arise, as it inevitably
will, WHO will need to consider patient treatment
regimes that will minimize the spread of resistance – not
to continue to manage individual malaria patients against
the extraordinarily unlikely possibility that every patient
will be the source of a second origin. There is no strong
argument for treating malaria as if it were a highly
mutable pathogen like HIV, and nor is it a bacterium
which can easily acquire resistance by lateral gene
transfer.
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magnitude of the costs of resistance
Much circumstantial evidence suggests that resistant
malaria parasites have a lower ﬁtness than sensitive para-
sites in the absence of chemotherapy (Walliker et al.
2005; Felger and Beck 2008). Suggestive evidence for a
cost of resistance comes from progressive increases in
drug sensitivity in populations where drug use has been
discontinued. This has been seen in Malawi (Kublin et al.
2003; Mita et al. 2003; Laufer et al. 2006), Tanzania
(Temu et al. 2006), South-Africa (Raman et al. 2008),
Thailand (Thaithong et al. 1988), and China (Liu et al.
1995), although there are also areas where a decrease of
resistance has not been observed (e.g. McCollum et al.
2007; Yang et al. 2007). Seasonal variation in the fre-
quency of resistant alleles in eastern Sudan and The
Gambia is also consistent with costs of resistance. When
there is low to no transmission during the dry season,
and hence few new malaria cases and essentially no drug
use, resistance alleles drop in frequency among the chron-
ically infected patients who source the next outbreak.
During the wet season, when high transmission ensures
many new disease cases and hence high drug usage, resis-
tance alleles rise in frequency (Abdel-Muhsin et al. 2004;
Ord et al. 2007).
As in other pathogens, costs of resistance in malaria
presumably arise from the metabolic costs of efﬂux or
detoxiﬁcation, or reduced biochemical efﬁciency associ-
ated with target site mutations (Hastings and Donnelly
2005); in other words, genetic trade-offs. Most models of
malaria drug resistance evolution recognize these costs of
resistance, but, if included at all, they are typically taken
as a ﬁxed and relatively modest parameter (e.g. a selective
disadvantage s, so that the ﬁtness of resistant mutant is
1 ) s, where s in the order of 0.1 or less). Although not
much discussed, we believe there is a widely held assump-
tion that these costs can be mitigated by compensatory
mutations, as they can be in bacteria and HIV (Levin
et al. 2000), so that s can drop further through time.
Such selection processes might explain some of the
sequential mutational steps associated with chloroquine
and SP resistance (Hastings and Donnelly 2005; Hastings
and Watkins 2006).
Yet the natural history of malaria makes it highly unli-
kely that the costs of resistance can be captured by a ﬁxed
parameter like ‘s’, and moreover suggests that the costs
can often be much larger under some ecologic circum-
stances. This is because the costs of resistance are a func-
tion of the interactions between coinfecting strains within
the host. Indeed, this in-host ecology maybe the primary
determinant of the magnitude of the costs of resistance.
The natural history is as follows.
Human malaria infections frequently consist of more
than one Plasmodium genotype (Arnot 1998; Babiker
et al. 1999; Smith et al. 1999; Bruce et al. 2000; Jafari
et al. 2004), so that coexistence of sensitive and resistant
parasites is common – and indeed may even be the rule,
especially when resistance is beginning to spread through
a population. Mixed infections arise from inoculations of
genetically diverse parasites by a single mosquito, or con-
temporaneous bites by multiple mosquitoes infected with
different parasites.
A substantial body of correlational epidemiologic evi-
dence is consistent with crowding effects within infec-
tions, where population densities of individual genotypes
are suppressed when other genotypes are present (Dau-
bersies et al. 1996; Mercereau-Puijalon 1996; Smith et al.
1999; Bruce et al. 2000; Hastings 2003; Talisuna et al.
2006). Direct experimental evidence of crowding cannot
be ethically obtained from human infections, but in the
rodent malaria model Plasmodium chabaudi in laboratory
mice, we and others have experimentally demonstrated
that strong crowding effects occur. Replicative and trans-
mission stage densities of individual clones within an
infection are severely suppressed when coinfecting
strains are present (e.g. Jarra and Brown 1985; Taylor
et al. 1997; de Roode et al. 2004, 2005; Bell et al. 2006;
Wargo et al. 2007). Competitive suppression within hosts
also substantially reduces transmission of individual
clones to mosquitoes (de Roode et al. 2005). Therefore,
the removal of sensitive strains by chemotherapy leads to
competitive release of resistant strains (de Roode et al.
2004; Wargo et al. 2007).
We have found in our experiments with rodent
malarias that differences in clone performance are greatly
magniﬁed by this crowding effect. An example is given in
Fig. 3. Pyrimethamine-resistant and sensitive clones are
shown. Alone, the resistance clone produces fewer trans-
mission stages. However, when the two clones coinfect
the same host, the difference is ampliﬁed by clonal com-
petition. We are currently doing experiments to see
whether this competitive disadvantage increases as more
sensitive coinfecting strains are added. In high transmis-
sion regions, infections can consist of ﬁve or more clones;
if crowding increasing with the number of clones, the ﬁt-
ness disadvantage of resistance could substantially increase
with the force of infection.
Thus, the within-host ecology is likely to be a primary
determinant of the strength of selection of any resistant
mutant in the absence of chemotherapy: the ecologic cir-
cumstances can magnify ﬁtness differences way beyond
those due simply to ecology-independent genetic trade-
offs (Hastings and D’Alessandro 2000; Mackinnon 2005;
Hastings 2006b). Except perhaps where single clone infec-
tions dominate (as can be the case in low transmission
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thing. Within-host genetic diversity is in turn determined
by the epidemiology (force of infection), since this is
what determines frequency of mixed infections in a popu-
lation. We suggest that standard population genetics
approaches to model drug resistance are likely to be of
very limited value in malaria. Explicit evolutionary epi-
demiologic models (Restif 2009) are needed instead. They
are in their infancy in this context (e.g. Hastings 2006b),
but there is no escaping this complexity: the epidemiology
determines the strength of selection and hence the evolu-
tion, and the evolution in turn determines the epidemio-
logic dynamics.
A highly contentious and unorthodox possibility is sug-
gested by the above considerations (Wargo et al. 2007).
Crowding by drug sensitive parasites will suppress trans-
mission stage densities of resistant parasites in untreated
hosts. This suggests it might be possible to harness these
within-host dynamics for human beneﬁt: the use of
patient treatment regimes which do not remove all the
sensitive parasites may restrict the transmission of resis-
tance. Some evidence that this might be feasible comes
from one of our experiments with rodent malaria (Wargo
et al. 2007). We found that treating mice with half the
normal dose of antimalarials alleviated the symptoms as
effectively as a full dose, but a degree of in-host competi-
tion was retained, with the consequence that the trans-
mission potential of the resistant clone was signiﬁcantly
less than in mice given standard doses. Considerably
more work needs to be done to evaluate the merits of
abandoning the parasitologic cure orthodoxy which cur-
rently form the basis of WHO (2006) patient treatment
guidelines, but we note that overwhelming chemotherapy
is also the way to most effectively up-select resistant
mutants in laboratory settings (e.g. Peters 1987), and that
host immunity can very effectively clear parasites, espe-
cially following drug treatment (Cravo et al. 2001). The
theoretical and experimental analysis of the possibility of
optimizing patient treatment regimes with respect to both
patient health and resistance management is long over-
due. For instance, would the best regime actually be what
is currently considered heretical: take drug treatment until
the patient feels better, then further treatment if there are
any symptom-associated relapses?
Fallacy 5: Fixation of resistance is inevitable if
drug pressure is maintained
A very interesting implication of in-host competition is
that the costs of resistance must be frequency-dependent.
When a resistant mutant ﬁrst becomes established in a pop-
ulation, it will typically share its host with competitively
more able sensitive strains. As resistance becomes more fre-
quent, resistant strains will increasingly share their hosts
with other resistant strains. Because competition magniﬁes
differences in competitive ability as described above, this
means that the costs of resistance will be highest early in
the spread process, and will decline as resistant strains are
increasingly likely to be competing with strains with similar
competitive abilities.
Moreover, the beneﬁts of resistance will be similarly fre-
quency dependent. For malaria, the beneﬁts of resistance
accrue from two sources: (i) improved survival in a drug-
treated host, and (ii) removal of competitors (Hastings and
D’Alessandro 2000; de Roode et al. 2004). This competitive
release, whereby the resistant clone is able to expand into
‘niche space’ emptied by chemotherapy has the potential to
greatly magnify the survival beneﬁts of resistance – and
indeed, it can shorten the therapeutically useful lifespan of
a drug many-fold below that expected if resistance evolu-
tion were powered only by the survival advantage (Hastings
and D’Alessandro 2000). Direct evidence of competitive
release cannot be ethically obtained for humans, but in
rodent malaria infections it is seen following both prophyl-
atic and therapeutic chemotherapy (Fig. 4; de Roode et al.
2004; Wargo et al. 2007). As this potent selective advantage
arises only when a resistant clone is in a coinfection with
sensitive clones, it will become progressively weaker as
resistance spreads in a population.
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Figure 3 An example of how competition between parasites within
infections magniﬁes differences in performance between sensitive and
resistant parasite lines. Top panel – the performance of the two
clones when in separate infections. Bottom panel – the performance
of the two clones together in the same infection. The lower perfor-
mance of the resistant clone is further lowered by competition. Plot-
ted points are the mean (±SEM) density of transmission stages of
Plasmodium chabaudi in peripheral blood through time from three to
six laboratory mice per group (S. Huijben, A. R. Wargo, B. H. K. Chan,
D. Drew, A. F. Read, unpublished data). Parasite densities were quan-
tiﬁed by real time quantitative RT-PCR (Drew and Reece 2007).
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the frequency of resistance in a population. Hastings
(2006b) has pointed out that this means that resistance
evolution is likely to have dynamics which are considerably
more complex than the standard S-shaped curve of rising
allele frequencies through time seen in introductory
population genetics textbooks. He suggests that this might
explain why, for several different countries and drugs, resis-
tance has apparently stabilized at frequencies well short of
ﬁxation (e.g. over 8 years in eastern Sudan, chloroquine
resistance ﬂuctuated seasonally around an apparently stable
equilibrium frequency of 40%; Babiker et al. 2005).
More generally, given the enormous regional and sea-
sonal variation in the force of infection, which is the
major determinant of the genetic diversity of malaria
infections (Arnot 1998), it may be that there are pro-
found regional differences in the patient treatment
regimes and drug deployment strategies which are opti-
mal for resistance management. Existing global recom-
mendations (WHO 2006) may be too simplistic.
Open questions
In addition to the unresolved issues which arise in the
context of the preceding fallacies, there are a very large
number of other open issues which seem to us unlikely to
be resolved without the input of professional evolutionary
biologists. Consider, for example, the following:
1 Why did resistance to chloroquine and SP become
established so rarely when resistance spread so globally?
In particular, why is so much drug resistance arising
in Southeast Asia? There are at least ﬁve hypotheses
(Klein et al. 2008), most of which focus on the
observation that drug resistance seems to have arisen
in areas of low or unstable transmission (White and
Pongtavornpinyo 2003).
2 Will vector control enhance the spread of drug resis-
tance? Historically, resistance seems to have emerged
predominantly in low-transmission areas and spread
more effectively in low transmission areas (White
2004; Klein et al. 2008). The large-scale deployment
of bednets envisaged by GMAP is aimed at reducing
malaria transmission (Roll Back Malaria 2008). Will
this lead to more rapid resistance evolution, and
necessitate a faster drug pipeline? The inﬂuence of
transmission rate on resistance evolution has been
hotly debated. Several arguments have been put for-
ward that high transmission intensity promotes the
spread of drug-resistance. Clonal diversity in infec-
tions is higher, exacerbating beneﬁts of resistance, as
discussed above. Higher transmission also means
that, for a given level of drug use, more parasites will
be exposed to drug selection (Mackinnon and Has-
tings 1998). On the other hand, genetically diverse
infections will generate more outcrossed progeny
infections, and will thereby lead to the destruction of
multi-locus resistance genotypes (Talisuna et al.
2004; Mackinnon 2005). Moreover, areas with low
transmission intensity typically harbor fewer immune
individuals, who have (i) a higher parasite biomass
and so more mutations (White and Pongtavornpinyo
2003), (ii) more symptomatic infections, and hence
stronger drug selection (Talisuna et al. 2004; Mack-
innon 2005), and (iii) a reduced capacity to clear
drug-resistant parasites (Cravo et al. 2001). How
these and other conﬂicting forces play out has yet to
be established.
3 Is the WHO-recommended radical parasite cure really
optimal for either patient treatment or resistance man-
agement? We have already questioned above whether
radical parasite cure really is the best way of both
treating patients and managing resistance evolution.
Analyses of the question could also consider the fol-
lowing. In high transmission regions, where people
receive more than one infective bite per day (Arnot
1998; Beier et al. 1999; Hay et al. 2000), does radical
cure of a symptomatic infection have a sufﬁciently
large clinical beneﬁcial effect to offset the greatly
enhanced exposure of parasites to drugs? Does com-
plete parasite clearance make it easier for new para-
sites to invade?
(A) (B)
Figure 4 Competitive release of resistant parasites following the
removal of sensitive competitors by chemotherapy. The total number
of resistant parasites present in infections where sensitive parasites
have been removed by drug treatment or allowed to remain (no
drugs) are shown. Plotted points are the mean (±SEM) cumulative
total number of Plasmodium chabaudi parasites present in peripheral
blood of mice, based on three to ﬁve infections per group. Therapeu-
tic treatment is applied when the hosts ﬁrst start to show symptoms
of malaria (weight loss, anemia); prophylactic treatment is applied at
the time host are infected. Data from Wargo et al. (2007), and de Ro-
ode et al. (2004) respectively.
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virulent parasites? Chemotherapy could enhance the
circulation of more virulent strains by keeping alive
patients who would otherwise have died from virulent
infections (Gandon et al. 2001; Porco et al. 2005). It
could also be that drug tolerance varies with virulence,
for instance if more rapidly replicating parasites are
more vulnerable to drugs (higher metabolic sensitiv-
ity) or less vulnerable (faster population recovery once
drug pressure has stopped). For one clonal lineage of a
rodent malaria, less virulent parasites were more
strongly suppressed by subcurative chemotherapy than
more virulent parasites, suggesting that virulence evo-
lution could indeed proceed in parallel with classical
resistance evolution (Schneider et al. 2008).
5 Will the HIV epidemic increase the rate of antimalar-
ial resistance evolution? There are about 18% more
malaria parasites in sub-Saharan Africa as a result of
the HIV-associated immunosuppression (Van Geer-
truyden et al. 2008). Does this increase in parasite
number increase the chance of resistance mutations
becoming established? If HIV-infection increases the
severity of malaria or impairs immune clearance, will
drug use become more common, strengthening the
selection for resistance?
Coda
We hope that this review of some recent work and ideas
in malaria drug resistance has made our general point
that, from the perspective of evolutionary science, there is
nothing fundamentally uninteresting or easy about drug
resistance – and that solutions to the issues could have
profound impacts on human health and wellbeing. Evolu-
tionary biologists could conceivably contribute as much
as drug discovery specialists (and much more cheaply). It
is very hard to imagine that the world will indeﬁnitely
fund a malaria drug discovery pipeline at $US1.5 billion
per decade, or indeed that there is an unlimited supply of
drug classes to be discovered. Using the compounds we
already have in the pipeline more effectively is a very high
priority. Evolutionary geneticists have and continue to
play a crucial role in reconstructing the history of drug
resistance (e.g. Fig. 2). The challenge is to add to this an
understanding of the processes that shaped this history,
and use that understanding to change the future.
For those evolutionary biologists interested in general
principles, the issues we have raised here in the context of
malaria are relevant across a diverse range of pathogens,
from RNA viruses to worms. Our bias is that, at least
when it comes to policy and patient treatment, there has
been too much focus on simple generalities and not
enough focus on the important consequences of disease-
speciﬁc natural history and indeed location-speciﬁc epide-
miology. It may also be that considering the drug resis-
tance problem alongside other problems of resistance
management, such as mosquito resistance to insecticides,
pest resistance to GM crops, and weed resistance to herbi-
cides, would provide novel insights for human health,
especially since for some of these, the evolutionary analysis
is more advanced (e.g. Labbe ´ et al. 2007), and evolution-
ary biologists have had a profound impact on policy and
implementation on the ground (e.g. Bates et al. 2005).
A major focus of evolutionary biology has been the
adaptation of traits where group and individual interests
conﬂict. This way of thinking will undoubtedly prove to be
a fertile area in drug resistance too, not least as a guide to
the identiﬁcation of drug targets (Andre and Godelle
2005). But there is also an urgent need to identify resis-
tance management strategies which are good for the group
(the currently uninfected, and the patients of the future)
without being detrimental to individual patients seeking
primary health care right now. In the limit, there is a
trade-off between patient treatment and resistance man-
agement (the latter being optimized when very few patients
are treated with a drug). But such trade-offs are extreme
cases. Even where it is necessary to treat effectively large
numbers of patients, there are many ways patients can be
treated, and among those that similarly restore patient
health will be some which are better at resistance manage-
ment than others. As we have pointed out above, clinical
cure is the object of patient treatment, and this need not
require parasitologic cure. From a public health perspec-
tive, what is the best way to treat patients, impact trans-
mission, and slow the spread of resistance?
More generally, there is a real need to engage with
those who deliver and receive health care, and the econo-
mists and social scientists who study the process. What
sort of resistance management strategies can patients,
physicians and public health planners cope with, particu-
larly if they involve an understanding of evolution?
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